- Home
- YGMZ vs GLMD Comparison
YGMZ vs GLMD Comparison
Compare YGMZ & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- GLMD
- Stock Information
- Founded
- YGMZ 2002
- GLMD 2000
- Country
- YGMZ China
- GLMD Israel
- Employees
- YGMZ N/A
- GLMD N/A
- Industry
- YGMZ Transportation Services
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- GLMD Health Care
- Exchange
- YGMZ Nasdaq
- GLMD Nasdaq
- Market Cap
- YGMZ 5.5M
- GLMD 6.6M
- IPO Year
- YGMZ 2020
- GLMD 2014
- Fundamental
- Price
- YGMZ $0.12
- GLMD $0.90
- Analyst Decision
- YGMZ
- GLMD Hold
- Analyst Count
- YGMZ 0
- GLMD 1
- Target Price
- YGMZ N/A
- GLMD N/A
- AVG Volume (30 Days)
- YGMZ 6.5M
- GLMD 6.3M
- Earning Date
- YGMZ 01-01-0001
- GLMD 11-26-2025
- Dividend Yield
- YGMZ N/A
- GLMD N/A
- EPS Growth
- YGMZ N/A
- GLMD N/A
- EPS
- YGMZ N/A
- GLMD N/A
- Revenue
- YGMZ $31,172,395.00
- GLMD N/A
- Revenue This Year
- YGMZ N/A
- GLMD N/A
- Revenue Next Year
- YGMZ N/A
- GLMD N/A
- P/E Ratio
- YGMZ N/A
- GLMD N/A
- Revenue Growth
- YGMZ N/A
- GLMD N/A
- 52 Week Low
- YGMZ $0.11
- GLMD $0.74
- 52 Week High
- YGMZ $24.64
- GLMD $3.61
- Technical
- Relative Strength Index (RSI)
- YGMZ 37.02
- GLMD 34.22
- Support Level
- YGMZ $0.93
- GLMD $0.74
- Resistance Level
- YGMZ $1.08
- GLMD $1.54
- Average True Range (ATR)
- YGMZ 0.13
- GLMD 0.13
- MACD
- YGMZ -0.05
- GLMD -0.02
- Stochastic Oscillator
- YGMZ 1.94
- GLMD 20.98
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.